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Abstract: Snakebite is a neglected disease and serious health problem in Brazil, with most 
bites being caused by snakes of the genus Bothrops. Although serum therapy is the primary 
treatment for systemic envenomation, it is generally ineffective in neutralizing the local 
effects of these venoms. In this work, we examined the ability of 7,8,3'-trihydroxy-4'-
methoxyisoflavone (TM), an isoflavone from Dipteryx alata, to neutralize the neurotoxicity 
(in mouse phrenic nerve-diaphragm preparations) and myotoxicity (assessed by light 
microscopy) of Bothrops jararacussu snake venom in vitro. The toxicity of TM was 
assessed using the Salmonella microsome assay (Ames test). Incubation with TM alone 
(200 μg/mL) did not alter the muscle twitch tension whereas incubation with venom  
(40 μg/mL) caused irreversible paralysis. Preincubation of TM (200 μg/mL) with venom 
attenuated the venom-induced neuromuscular blockade by 84% ± 5% (mean ± SEM;  
n = 4). The neuromuscular blockade caused by bothropstoxin-I (BthTX-I), the major 
myotoxic PLA2 of this venom, was also attenuated by TM. Histological analysis of 
diaphragm muscle incubated with TM showed that most fibers were preserved (only  
9.2% ± 1.7% were damaged; n = 4) compared to venom alone (50.3% ± 5.4% of fibers 
damaged; n = 3), and preincubation of TM with venom significantly attenuated the  
venom-induced damage (only 17% ± 3.4% of fibers damaged; n = 3; p < 0.05 compared to 
venom alone). TM showed no mutagenicity in the Ames test using Salmonella strains 
TA98 and TA97a with (+S9) and without (−S9) metabolic activation. These findings 
indicate that TM is a potentially useful compound for antagonizing the neuromuscular 
effects (neurotoxicity and myotoxicity) of B. jararacussu venom. 
Keywords: ames test; bothropstoxin-I; 7,8,3'-trihydroxy-4'-methoxyisoflavone; neuromuscular 
junction; Salmonella mutagenicity; snake venoms 
 
1. Introduction 
Envenomation by Bothrops snakes is characterized by local (pain, edema, inflammation, blistering, 
hemorrhage and necrosis) and systemic (coagulopathy, systemic hemorrhage, acute kidney injury and 
circulatory shock) manifestations [1]. Bothrops jararacussu is a large pit viper found in southeastern 
Brazil and northern Argentina [2]. Envenomation by this species shares many of the foregoing features 
with other Bothrops species [3], with most of the clinical manifestations of envenoming being 
mediated predominantly by snake venom metalloproteases (SVMPs), serine proteases, phospholipases 
(PLA2) and C-type lectins. Transcriptomic analysis has confirmed that these are indeed the major 
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protein classes in this venom, with PLA2 being particularly abundant: Lys49-PLA2 homologs 
accounted for 83.2% of PLA2 transcripts, acidic Asp49-for 0.6% and basic Asp49-PLA2 for 0.1% [4]. 
In addition to the features indicated above, clinical studies in the early 1900s suggested that bites by 
B. jararacussu also involved systemic manifestations reminiscent of envenoming by the South 
American rattlesnake, Crotalus durissus terrificus, viz., neurotoxicity, blindness, blurred vision, 
difficulty in swallowing and paralysis [5], in addition to other unspecified signs of neurotoxicity [6–8]. 
In agreement with this, various studies using isolated vertebrate nerve-muscle preparations in vitro 
have shown that B. jararacussu venom [9,10] and PLA2 from this venom [11–16] can cause 
neuromuscular blockade by pre- and post-synaptic mechanisms. 
Serum therapy, the treatment of choice for snakebites, efficiently neutralizes the systemic manifestations 
but is generally ineffective against the local effects (edema, inflammation, hemorrhage and necrosis) of 
venoms [17]. Extensive local tissue damage leading to tissue loss after Bothrops bites can result in 
permanent disability and amputations [18,19]. Hence, there is a clinical and therapeutic impetus to 
develop alternatives for treating these local manifestations, with plant-derived bioactive products 
providing important candidate or lead molecules [20,21]. 
Several studies have shown that the neurotoxic and myotoxic effects of B. jararacussu venom and 
its PLA2 myotoxins can be neutralized by some plant extracts and their isolated compounds [21–30]. 
In particular, a methanolic extract of bark from Dipteryx alata Vogel, a plant species native to the 
Brazilian cerrado, fully protects against the neuromuscular blockade caused by B. jararacussu venom, 
whereas a dichloromethane extract provides partial protection against the blockade caused by  
B. jararacussu and C. d. terrificus venoms [31]. Lupane triterpenoids (lupeol, lupenone, betulin and 
28-OH-lupenone) from D. alata prevent the paralysis induced by B. jararacussu venom [32], whereas 
betulin and lupenone only partially neutralize the paralysis induced by C. d. terrificus venom [33]. 
To increase our understanding of the components involved in the protective action of D. alata 
extracts, in this study we examined the ability of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM),  
an isoflavone from D. alata [32], to attenuate the neurotoxicity and myotoxicity of B. jararacussu 
venom and its main myotoxin, bothropstoxin-I (BthTX-I), in mouse phrenic nerve-diaphragm 
preparations in vitro. The mutagenicity (toxicity) of TM, as an indicator of it potential use as a clinical 
agent, was assessed in the Ames test using Salmonella strains TA 98 and TA 97a. 
2. Results and Discussion 
This work was based on three premises: (1) an understanding of the principal clinical manifestations 
of B. jararacussu envenomation [1]; (2) the low efficacy of antivenom against the local effects of 
Bothrops venoms [18,19]; and (3) the availability of a molecule, 7,8,3'-trihydroxy-4'-methoxyisoflavone 
(TM) from D. alata, with potentially interesting activity against B. jararacussu snake venom. 
2.1. Molecule 
Figure 1 shows the chemical structure of TM from D. alata [32], a compound also found in 
Xanthocercis zambesiaca (Baker) plant extract [34]. 
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Figure 1. Chemical structure of 7,8,3'-trihydroxy-4'-methoxyisoflavone isolated from  
D. alata Vogel [32]. 
 
In preliminary screening for anti-snake venom activity, fraction F7 of a dichloromethane extract of 
D. alata bark [32] showed the best activity out of 11 fractions when tested against the neuromuscular 
activity of B. jararacussu venom [31]. Isoflavonoids are a large and very distinctive subclass of 
flavonoids, but only a few plants, including D. alata, have been reported to contain isoflavonoids [35]. 
Isoflavones are biologically active plant-food constituents that are common in the human diet and food 
industry, and are widely used as preservatives in pharmaceutical products [36]. This range of activities 
and uses suggested the possibility that isoflavones could be potentially useful as an adjuvant treatment 
for snakebites alongside standard serum therapy, particularly since antiserum shows little or no 
neutralizing activity towards the local effects of Bothrops venoms [18,19]. 
2.2. Pharmacological Assays 
The ability of TM to inhibit the neuromuscular blockade caused by B. jararacussu venom was 
investigated in mouse phrenic nerve-diaphragm (PND) preparations. Figure 2 shows the characteristic 
irreversible neuromuscular blockade induced by B. jararacussu venom in vitro (Bjssu, 40 µg/mL, n = 6, 
* p < 0.05 compared to control), in agreement with that originally reported by Rodrigues-Simioni et al. [9]. 
Incubation with TM alone (200 µg/mL, n = 4) did not change the muscle twitch-tension responses, 
which were similar to those of preparations incubated with Tyrode solution (negative control; n = 6). 
Preincubation of TM (200 µg/mL) with venom (40 µg/mL) for 30 min prior to testing totally abolished 
the venom-induced neuromuscular blockade (n = 4, * p < 0.05 compared to venom alone). 
Bothrops jararacussu venom is rich in PLA2, most of which are Lys49-PLA2, with considerably 
fewer basic and acidic Asp49-PLA2 [4]. Bothropstoxin-I (BthTX-I) is the major Lys49-PLA2 myotoxin 
and totally reproduces the in vitro neurotoxicity and myotoxicity of B. jararacussu venom [11]. This 
toxin acts presynaptically before causing membrane depolarization [15,37]. As shown in Figure 3A, 
incubation of PND preparations with BthTX-I (20 µg/mL) mimicked the characteristic progressive, 
irreversible decrease in muscle twitch-tension caused by the venom. As with the venom, preincubation 
of BthTX-I (20 µg/mL) with TM (200 µg/mL) fully protected the PND against toxin-induced 
neuromuscular blockade (Figure 3B). When TM was added 10 min after BthTX-I there was still 
attenuation of the neuromuscular blockade, although this was much less marked than with the 
preincubation protocol (Figure 3C). These findings suggest that the protective action of TM against 
venom-induced neuromuscular blockade most likely resulted from the inhibition of BthTX-I, 
presumably by attenuating the presynaptic activity of the toxin [15,37]. 
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Figure 2. Twitch tension responses of indirectly stimulated PND incubated with  
7,8,3'-trihydroxy-4'-methoxyisoflavone (TM, 200 μg/mL), B. jararacussu (Bjssu) venom  
(40 μg/mL) or a mixture of TM (200 µg/mL) and venom (40 μg/mL). The TM + venom 
mixture was preincubated at 37 °C for 30 min prior to testing. The points are the mean  
± SEM of the number of experiments indicated in the figure. * p < 0.05 for TM + venom 
compared to venom alone. 
 
Figure 3. Neuromuscular responses of indirectly stimulated PND incubated with BthTX-I 
(20 µg/mL) in the absence (A) and presence (B,C) of 7,8,3'-trihydroxy-4'-methoxyisoflavone 
(TM, 200 µg/mL). In (B), TM (200 µg/mL) was preincubated with BthTX-I (20 µg/mL) at 
37 °C for 30 min before addition to the bath, whereas in (C) TM (200 µg/mL) was added 
separately (at *) 10 min after the addition of BthTX-I (20 µg/mL). Arrows show the 
moment of sample addition to the bath. Bar = tension of 5 g/cm; W = wash. 
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2.3. Quantitative Histological Analysis 
To assess the anti-myotoxic activity of TM, diaphragm muscles exposed to different treatments 
(TM, venom or TM + venom) were analyzed by light microscopy, as described by Queiroz et al. [38] 
for mouse tibialis anterior muscle. Figure 4A shows a characteristic myographic recording of PND 
contractile activity during incubation with TM (200 µg/mL) for 120 min; similar responses were 
observed in preparations incubated with Tyrode solution alone (results not shown). The percentage  
of damage cells in these two protocols was <10% [9.7% ± 1.6% (n = 6) for Tyrode solution and  
9.2% ± 1.7% (n = 4) for TM-treated muscles]. 
Figure 4. Histological analysis of muscle damage in PND incubated with or without  
7,8,3'-trihydroxy-4'-methoxyisoflavone (TM). Panel (A) shows a representative trace of 
PND incubated with TM (n = 4). The arrow indicates the addition of TM. Bar = tension of 
5 g/cm. W = wash. Panels B and C show cross-sections of diaphragm muscle incubated 
with Tyrode solution alone (negative control; n = 6) (B) or TM alone (n = 4) (C). Note the 
normal appearance of the fibers (polygonal aspect and peripheral nuclei) in both panels. 
Bar = 50 μm in B and C. 
 
In indirectly stimulated PND, B. jararacussu venom (40 μg/mL, n = 6) induced a transient 
contracture that was followed by progressive neuromuscular blockade of muscle twitches during the 
following 120 min (Figure 5A). In contrast to the foregoing controls, there was a marked increase in 
the percentage of damaged fibers (to 50.3% ± 5.4%; p < 0.05 compared to the Tyrode control) in 
diaphragms incubated with venom alone (40 μg/mL, n = 3) for 120 min (Figure 5B). In diaphragm 
muscle incubated with a mixture of TM (200 μg/mL) + venom (40 μg/mL) (Figure 5C, n = 3) there 
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was a significant decrease in the percentage of damaged fibers (17% ± 3.4%; p < 0.05 compared to 
venom alone). Although the venom produced complete neuromuscular blockade, quantitative analysis 
of the fibers showed that only 50% were damaged. This discrepancy may reflect the fact that muscle 
cross-sections do not allow observation of the entire fiber length. Although diaphragm muscle has a 
high resistance to fatigue and a safety margin of 10% [39], the venom nevertheless had a striking effect 
on the physiological excitation-contraction coupling mechanism. As shown here, the preincubation of 
venom with TM was effective in protecting the muscle against venom-induced myotoxicity. 
Figure 5. Neuromuscular responses of indirectly stimulated PND incubated with  
B. jararacussu venom (40 μg/mL) for 120 min (A). Notice the irreversible blockade. 
Venom was added at the arrow. Bar = tension of 5 g/cm. W = wash. Panel (B)—Cross-section 
of diaphragm muscle incubated with venom alone (40 μg/mL, n = 6). Note the edema and 
intense myonecrosis (muscle fiber atrophy, hyaline aspect, sarcolemmal disruption and 
myofibril lysis). Panel (C)—Cross-section of diaphragm muscle incubated with a mixture 
of TM (200 μg/mL) + venom (40 μg/mL). Note the normal appearance of the fibers 
(polygonal aspect and peripheral nuclei), but with occasional edema. Bar = 50 μm for  
B and C.  
 
In this work, we focused on the ability of TM to antagonize the neuromuscular action (neurotoxicity 
and myotoxicity) of B. jararacussu venom and its main PLA2 myotoxin, BthTX-I. However,  
B. jararacussu venom has a variety of other biological activities (edema-formation, hemorrhage and 
lethality) against which it would be interesting to assess the neutralizing capacity of TM. Nevertheless, 
with the isolation procedure used in this study, the amount of isoflavone obtained was low, which 
severely limited the number of protocols and activities that could be tested. This limitation (low 
yield/availability of purified TM) is common to other phytochemical compounds with biological 
activity [40]. Nonetheless, as shown here, TM faithfully mimicked the protection against the  
venom-induced neuromuscular blockade seen with a crude extract of D. alata [31]. 
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Several mechanisms have been proposed to explain the anti-snake venom activity of phytochemical 
compounds [21], with the specific interactions depending on the plant compound (tannins, coumarins, 
flavonoids, etc.) and the snake genus involved. In the case of TM, we suggest that its interaction with 
B. jararacussu venom and BthTX-I involves the hydroxyl groups at positions C-8 and C-7 of the 
isoflavone (see Figure 1). Since the neighboring hydroxyls are susceptible to radical formation [35], 
this chemical interaction would ultimately lead to a very reactive 7,8-quinone moiety that could 
modify specific sites in enzymes responsible for the local and systemic effects of the venom. 
2.4. Salmonella Mutagenicity Assay 
The toxicology of TM was assessed in the Salmonella mutagenicity assay, using test strains TA97a 
and TA98 that can be reverted by frameshift mutagens [41,42]. Although the Organisation for 
Economic Cooperation and Development (OECD) [41] recommends the use of at least five Salmonella 
strains to meet regulatory demands, the low yield of isoflavonoid limited the use of five strains in this 
work. On the other hand, satisfactory toxicological results have been obtained using only TA97a and 
TA98 [43] or TA97a and TA100 [44], and were considered as valid mutagenic screening. In our 
experimental conditions a GC frameshift was evaluated. The mutagenicity assays showed that TM did 
not increase the number of revertant colonies relative to the negative control, indicating no 
mutagenicity for this compound (Table 1). 
Table 1. Assessment of the mutagenicity of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM) 
against S. typhimurium. The table shows the revertants per plate, the standard deviation and 
the mutagenicity index (in brackets) for strains TA98 and TA97a after treatment with TM. 
TM 
Treatment TA 98 TA 97a 
mg/plate −S9 +S9 −S9 +S9 
DMSO 20 ± 2 30 ± 2 151 ± 8 143 ± 8 
0.19 20 ± 4 (1.0) 34 ± 3 (1.1) 194 ± 4 (1.3) 172 ± 4 (1.2) 
Control+ 1319 ± 41 a 1696 ± 41 b 1875 ± 62 a 1623 ± 48 b 
The values are the mean ± SEM of two determinations. DMSO: dimethyl sulfoxide (50 μL/plate; negative 
control); Control+: positive control; a 4-nitro-o-phenylenediamine (10 μg/plate); b 2-anthramine (1.25 μg/plate). 
The genes affected in Salmonella strains TA98 and TA97a were hisD6610 and hisD3052, 
respectively, although these strains also contained the mutations ∆urvB, rfa and pKM101. The former 
was designed to enhance the mutagenicity of compounds, presumably through the nucleotide excision 
repair system [42] that extended into a gene for biotin synthesis and required the addition of biotin to 
the culture medium because of the deletion in this region. The rfa mutation changes the properties of 
the bacterial cell wall and results in partial loss of the lipopolysaccharide (LPS) barrier, thereby 
increasing the permeability of cells to certain chemicals; this mutation is generally detected based on 
the altered sensitivity to crystal violet. The R factor plasmid (pKM101) makes the strains more 
responsive to a variety of mutagens [45]. 
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3. Experimental 
3.1. Plant Material and Extraction 
Bark samples were collected from an adult D. alata Vogel tree in Pedro Afonso (Tocantins, Brazil) 
in December 2007 and identified by Dr. Roseli B. Torres (Institute of Agronomy of Campinas—IAC). 
A voucher specimen was deposited in the herbarium of the IAC (IAC 50629). The bark (1.269 kg)  
was dried at 37 C for 48 h and then powdered, ground in a mill, macerated for 5 days (200 g in 2 L of 
70% ethanol) and the suspension then percolated (protected from light) at 20 drops/min, resulting  
in a 20% (m/v) hydroalcoholic extract. The extract was concentrated under reduced pressure and 
lyophilized to yield a final residue of 170 g that corresponded to an extraction efficiency of 85% [46]. 
3.1.1. Isolation of 7,8,3'-trihydroxy-4'-methoxyisoflavone 
For isolation of the isoflavone, lyophilized extract (50 g) was dissolved in a methanol/water mixture 
(80:20, v/v) and partitioned successively with the corresponding solvents to yield, after concentration, 
hexane (1.5 g), CH2Cl2 (18 g), EtOAc (3.7 g) and MeOH (21 g) residues. The CH2Cl2 fraction was 
subjected to silica gel flash column chromatography and eluted with hexane/EtOAc (9:1). This 
procedure yielded 12 subfractions that were further successively flash-chromatographed on silica gel 
and purified by Sephadex LH-20 column chromatography and eluted with hexane/CH2Cl2/MeOH 
(2:2:1) to yield 18 compounds, including 19 mg of 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM), 
characterized 32 as a yellow amorphous solid. IR (KBr) cm−1: 3429, 1619, 1604, 1290, 1124.  
1H-NMR (CD3OD) δ: 3.80 (s, 3H), 6.93 (s, 1H), 6.94 (d, J = 8.7 Hz, 1H), 6.96 (s, 1H), 7.03 (s, 1H), 
7.57 (d, J = 8.7 Hz, 1H), 8.17 (s, 1H). 13C-NMR (CD3OD) δ: 56.4 (CH3), 112.6 (CH), 115.4 (CH), 
117.3 (CH), 117.4 (CH), 118.8 (C), 121.6 (CH), 125.3 (C), 126.3 (C), 134.1 (C), 147.4 (C), 147.8 (C), 
149.2 (C), 171.0 (C), 154.6 (CH), 178.5 (C). 
3.1.2. Isoflavone Solubilization 
For the pharmacological assays, fresh solutions of TM were prepared daily by dissolving in 30 µL 
of DMSO (CAQ – Casa da Química Ind. E Com. Ltd, Diadema, SP, Brazil); this volume of solvent did 
not alter the basal response of the neuromuscular preparation [47,48]. 
3.2. Pharmacological Assays 
3.2.1. Venom and Purification of BthTX-I 
Bothrops jararacussu venom was collected from two adult specimens kept in the Serpentário do 
Centro de Estudos da Natureza (CEN). The venom was lyophilized and certified by Dr. José Carlos 
Cogo (Vale do Paraiba University—UNIVAP, São José dos Campos, SP, Brazil). BthTX-I was 
purified and its identity confirmed as described by Homsi-Brandeburgo et al. [11]. 
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3.2.2. Animals 
Male Swiss white mice (26–32 g) were supplied by Anilab (Animais de Laboratório, Paulínia, SP, 
Brazil). The animals were housed at 25 ± 3 C on a 12 h light/dark cycle and had access to food and 
water ad libitum. This project was approved by the institutional Committee for Ethics in Animal 
Research of Vale do Paraiba University (protocol no. A013/CEUA/2011) and the experiments  
were done in accordance with the general guidelines of the Brazilian Society for Laboratory Animal 
Science (SBCAL). 
3.2.3. Mouse Phrenic Nerve-Diaphragm Muscle (PND) Preparation 
The PND preparation [49] was obtained from mice anesthetized with halothane (Cristália, Itapira, 
SP, Brazil) and killed by exsanguination. The diaphragm was removed and mounted under a tension of 
5 g/cm in a 5 mL organ bath containing aerated Tyrode solution (control) of the following composition 
(mM): NaCl 137, KCl 2.7, CaCl2 1.8, MgCl2 0.49, NaH2PO4 0.42, NaHCO3 11.9 and glucose 11.1. 
After equilibration with 95% O2/5% CO2 (v/v), the pH of this solution was 7.0. The preparations were 
indirectly stimulated with supramaximal stimuli (4× threshold, 0.06 Hz, 0.2 ms) delivered from a 
stimulator (model ESF-15D, Ribeirão Preto, SP, Brazil) to the nerve by bipolar electrodes. Isometric 
twitch tension was recorded with a force displacement transducer (cat. no. 7003, Ugo Basile, Varese, 
Italy) coupled to a 2-channel Gemini physiograph recorder (cat. no. 7070, Ugo Basile) via a basic 
preamplifier (cat. no. 7080, Ugo Basile) [33]. The preparations were allowed to stabilize for at least  
20 min before initiating the treatments described below. 
Control preparations were incubated with Tyrode solution alone (n = 6), whereas other preparations 
were incubated with TM (200 µg/mL, n = 4), venom (40 µg/mL, n = 6) or a mixture of TM + venom 
preincubated for 30 min at 37 °C prior addition to the organ bath (n = 4) [33]. BthTX-I (20 µg/mL) 
was assayed in two protocols: in one, PND preparations were incubated with toxin followed by the 
addition of TM (200 µg/mL) while in the other the toxin was preincubated with TM (200 µg/mL) prior 
to testing in PND. 
3.2.4. Quantitative Histological Analysis 
At the end of the incubations (120 min), the preparations from the various protocols (control, TM, 
venom and venom + TM) were processed for histological analysis. The preparations (n = 3 for each 
treatment) were fixed in Bouin solution and processed by routine morphological techniques.  
Cross-sections (5 µm thick) of diaphragm muscle were stained with 0.5% (w/v) hematoxylin-eosin for 
examination by light microscopy. Tissue damage (edema, intense myonecrosis characterized by 
muscle fiber atrophy, a hyaline aspect, sarcolemmal disruption and myofibril lysis) was expressed as a 
myotoxicity index (MI), defined as (the number of damaged muscle cells/the total number of cells)  
× 100 in three non-overlapping, non-adjacent areas of each preparation [28]. 
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3.2.5. In vitro Mutagenicity Assay 
Mutagenic activity was evaluated by the Salmonella microsome assay, using the Salmonella 
typhimurium test strains TA98 and TA97a, kindly provided by Dr. B.N. Ames (Berkeley, CA, USA), 
with (+S9) and without (−S9) metabolization, by the preincubation method [50]. As discussed in the 
Results section, the OECD [41] recommends the use of five strains (S. typhimurium 1535, TA97a, 
TA98, TA100, TA102), but this was not feasible in this study because of the low yield of isoflavonoid 
during extraction. The strains were grown from frozen cultures overnight for 12–14 h in Oxoid 
Nutrient Broth No. 2. The metabolic activation mixture (S9 fraction), prepared from livers of  
Sprague–Dawley rats treated with the polychlorinated biphenyl mixture Aroclor 1254 (500 mg/kg), 
was purchased from Molecular Toxicology Inc. (Boone, NC, USA) and freshly prepared before each 
test. The metabolic activation system consisted of 4% S9 fraction, 1% 0.4 M MgCl2, 1% 1.65 M KCl, 
0.5% 1 M D-glucose-6-phosphate disodium, 4% 0.1 M NADP (nicotinamide adenine dinucleotide 
phosphate), 50% 0.2 M phosphate buffer and 39.5% sterile distilled water. The isoflavone was 
dissolved in DMSO (Sigma Chemical Co., St. Louis, MO, USA) to provide a non-toxic concentration 
of 0.19 mg/plate. This concentration was added to 0.5 mL of 0.2 M phosphate buffer, or to 0.5 mL of 
4% S9 mixture, with 0.1 mL of bacterial culture and then incubated at 37 °C for 20–30 min. 
Subsequently, 2 mL of top agar [0.6% agar, histidine and biotin (0.5 mM each) and 0.5% NaCl] was 
added and the mixture poured onto a plate containing minimal agar. The plates were incubated at  
37 °C for 48 h and the His+ revertant colonies were counted manually. All experiments were done 
only in duplicate because of the low amount of isoflavone available. The use of duplicate plating is 
acceptable when scientifically justified [41]. The results were analyzed with the statistical software 
package Salanal 1.0 (U.S. Environmental Protection Agency, Monitoring Systems Laboratory,  
Las Vegas, NV, from Research Triangle Institute, Research Triangle Park, NC, USA), using the model 
of Bernstein et al. [51]. The mutagenic index (MI), defined as the average number of revertants per 
plate with the test compound divided by the average number of revertants per plate with the negative 
(solvent) control, was also calculated. A sample was considered positive when the MI was equal to  
or greater than two for at least one of the concentrations, and if it had a reproducible dose-response 
curve [52]. The standard mutagen used as a positive control in experiments without the S9 mix was  
4-nitro-o-phenylenediamine (NOPD, 10 μg/plate). In experiments with S9 activation, 2-anthramine  
(2-AA, 1.25 μg/plate) was used. DMSO (50 μL/plate) served as the negative (solvent) control. 
3.2.6. Statistical Analysis 
Each pharmacological protocol was repeated at least four times and the results are shown as the 
mean ± SEM. The number of experiments (n) is indicated in the corresponding figure legend. 
Student’s t-test was used for statistical comparison of the data and the confidence level was set as 5% 
(α = 0.05). 
4. Conclusions 
In conclusion, the bioactive isoflavone, 7,8,3'-trihydroxy-4'-methoxyisoflavone (TM) from D. alata 
Vogel efficiently counteracted the myotoxicity and neuromuscular activity of B. jararacussu venom 
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and its major myotoxin, BthTX-I, in vitro. TM was not mutagenic in S. typhimurium strains TA 97a 
and TA 98, indicating its safety. The results of this study reinforce the potential of TM for therapeutic 
use in the treatment of venomous snakebites. 
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